Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
H.R.1507 - Health Outcomes, Planning, and Education for Alzheimer's Act
https://www.govtrack.us/congress/bills/113/hr1507/text
In 2010, Dr. Permutt and I could publish another paper showing that Wolfram is ER disease. Around this time, many researchers and doctors became interested in my theory. In 2011, I gave more than 30 lectures around the world on this topic, received a tenure from the University of Massachusetts Medical School, and was elected to the American Society For Clinical Investigation because of my contribution to the Wolfram syndrome and diabetes research, one of the highest honors as a young physician. However, I was feeling that I was at dead end and seriously thinking about leaving research and academic medicine because of several reasons. However, two incidents brought me back to research.
http://ir.stockpr.com/amarantus/company-news/detail/1024/amarantus-licenses-manf-related-wolframs-and-diabetes-therapeutic-and-diagnostic-intellectual-property-from-university-of-massachusetts-medical-school
Its all coming together nicely!!! GO AMB$
People.. as an investor in a penny stock we all know it's a roller coaster. There will be ups and there will be downs. I feel like there are some longs on here who unfortunately are too deep with their positions because of possible greed. Invest what you are capable of losing 100% and ride it all the way. A great saying I read was if you can't sleep you are probably in too deep.
good eye seebisquick
Fibonacci = gurevich ?
Somebody made this potential connectiom before but this could be the reason why he knew about BU:
Mikhail Gurevich (ENG’07), managing partner at the New York-based hedge fund Dominion Capital, received the Distinguished Young Alumni award, which honors outstanding alumni within ten years of graduation. Gurevich is an avid entrepreneur who started his first startup, ClickFacts, a Web security and analytics company, during his sophomore year at BU, and in 2007 cofounded ZepInvest, an information distribution platform for financial services firms that works with several Fortune 500 companies. Currently pursuing his MBA at BU, he leads and raises money for the Technology Entrepreneurs Club, which brings together students from the College of Engineering and the School of Management in the Engineering Entrepreneur Design Contest.
I find AMBS analogous to a college party.. All the pretty girls and guys are there talking about how epic the party is going to be.. We show up a little late but we are the ones bringing the booze and the party begins!!
Bernard J. Tyson CEO of Kaiser Permanente
This might be in left field.. but an insurance company would surely profit if they knew the future!!
Ive never been one to follow the trend. I do what I like and what makes me happy. I live life for myself and my loved ones. Holding long.. GLTA
He needs to add at the bottom..
Just sayin... ;)
CD-69(us) vs Tau(them)
In a study by Arendt and colleagues,3 the expression of a protein involved in white blood cell (WBC) production (CD-69) was measured on multiple cell lines of subjects with probable Alzheimer’s disease (n=32), healthy controls (n=30), and other dementias, namely Parkinson’s disease (n=26). CD-69 values showed variations in levels that allowed the researchers to differentiate between patients with Alzheimer’s disease (91% accuracy) and those with Parkinson’s disease (92% accuracy). The levels also distinguished people with Alzheimer’s disease from normal subjects 88% of the time when they had Alzheimer’s disease and 82% of the time when they had no cognitive deficits
http://primarypsychiatry.com/recent-advances-in-dementia-research/
Eltoprazine for the treatment of weight disorders:
Patent: US 20120190690 A1
Eltoprazine for the treatment of anxiety:
Patent: US 20120136005 A1
If you are a long and not flipping.. I find leaving and letting the boards go for a day or two really decreases the daily grind. Things take time and today is no different. We all know what we have.. enjoy a beer or two !!
In your opinion, would 1MM+ shares allow someone to retire and live out their 50+ years in a expensive city SF, LA, NY with daily luxury? I'm only daydreaming!!
If people like french food. I can see what I can do about French Laundry up in Napa after we visit QB3! A fine dining experience for our fine taste in biotech! Count me in!!
I have to agree.. Some on here have to trade because this is their income. They may depend on this to pay the bills. I can understand their frustrations but thank goodness I am in a position where I can freely sit on this stock indefinitely if I wanted to. Long AMBS!
Who wants to group buy on some MANF and do our own study!?
Country of Origin=USA... AMBS!!!
http://www.peprotech.com/en-US/Pages/Product/Recombinant-Proteins/Neurotrophins/Recombinant_Human_MANF/450-06
Risk, come back when you are ready! AMBS direction has been set and mission control will take it where it needs to go!
Caught a couple of typos:
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with NEURODEGENERATION and PROTEIN MISFOLDING-related apoptosis. The company has LICENSED ELTOPRAZINE, a Phase 2B ready Parkinsons Levadopa induced DYSKINESIA. The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the DISCOVERY of neurotrophic FACTORS ("PhenoGuard"). For further information, please visit www.Amarantus.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.
I cannot agree more...
Haters gonna Hate
I don't judge those that flip penny stocks on the daily.. but I find for myself that I would rather take my money to Vegas. You can find me at a craps table enjoying my Newcastles and 7&7'S.. good luck longs!!
Successfully locked my Rollover IRA into my ROTH. Picked more shares out of weak hands and stomachs. Seat belt fastened. Good to go!
The guy before Gerald mentioned some kind of technical difficulties to explain why they were presenting later than their scheduled slot.
He started speaking approx around 1440
Looks like BD is going to have to some $erious deci$ion$ to make since others guys are courting our lovely AMB$..
Regarding the #C4CT conference on Jan 29th. Johnson and Johnson have their hands in 2 of the 3 supporting partners of the conference. Banyan Biomarkers and One Mind... hmmm...
WarpCore.. sounds like a good plan you have there. Im going to look into it.
Im split with my holdings between my Roth IRA and Rollover IRA. I unfortunately didnt convert my Rollover into a Roth and I'm far from 59.5. So uncle sam will get a cut if I want to enjoy any of the earnings!
Johnson and Johnson looks to be involved in them too.
"Alachua-based Banyan Biomarkers received a $13 million Department of Defense contract to adapt its blood test that diagnoses traumatic brain injury to work with a lab test device made by Ortho Clinical Diagnostics, a subsidiary of Johnson & Johnson."
Hi all. I've been a lurker but a recently new long with AMBS.. excited for whats to come!
Banyan gets $13 million Defense Dept. grant
Published: Thursday, October 3, 2013 at 5:04 p.m.
Last Modified: Thursday, October 3, 2013 at 5:04 p.m.
http://www.gainesville.com/article/20131003/articles/131009839#gsc.tab=0